Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
US Yen Intervention Unlikely to Deliver Lasting Recovery, Yardeni Says 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
South Korean Won Leads Asian FX Losses as Dollar Rises 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Japan Posts First Current Account Deficit in 17 Months as Dividend Payments Surge 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Asian Currencies Steady as Markets Await U.S. Inflation Data 
S&P 500, Nasdaq Futures Rise as Iran Risks and CPI Loom 
US Stock Futures Flat as Iran Strait of Hormuz Demands Fuel Oil Concerns 
South Korea’s Hanmi Pharm Co., Celltrion Inc., and Dongbang FTL were among 27 drugmakers chosen to produce low-cost versions of Merck & Co.’s COVID-19 pill molnupiravir for low- and-middle-income countries.
The Medicines Patent Pool (MPP), an UN-backed public health organization, announced that it signed sublicense agreements with 27 generic drug manufacturers to produce molnupiravir to be supplied to 105 countries.
Celltrion will manufacture the finished drug and Dongbang FTL will produce ingredients, while Hanmi will do both.
The MPP signed a licensing agreement with the US drugmaker last year to boost global access for molnupiravir.
The South Korean government would support its three pharmaceutical companies involved in the deal by easing regulations and establishing a consultative entity involving government ministries and companies.
According to MPP, which works to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries, the companies offered the sublicense have demonstrated their ability to meet its requirements for production capacity, regulatory compliance, and the ability to meet international standards for quality-assured medicines.
The MPP’s list of 27 generic manufacturers also includes 10 Indian and two Chinese firms.
Out of the 27 companies, 13 will produce both raw ingredients and the finished drug, according to the MPP.
